

**Drugs and Therapeutics (D & T) Committee  
Meeting Results  
November 13, 2019**

<b>Drug Name</b>	<b>Review Type</b>	<b>Committee Recommendation</b>	<b>Prior Approval Status – Final Determination</b>
Cablivi	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Mavenclad	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Olumiant	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Skyrizi	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Spravato	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Envarsus XR	New Drug Appeal	Table decision pending further data	Non-preferred requires PA until a final recommendation is rendered
Trulicity	New Drug Appeal	Non-preferred requires PA	Non-preferred requires PA
Zepatier	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA